Michel C Nussenzweig

List of Publications by Year
in descending order

249 papers	53,303 citations	830 112 h-index	956 226 g-index
320 all docs	320 docs citations	320 times ranked	52199 citing authors

#	Article	IF	Citations
1	Affinity maturation of antibody responses is mediated by differential plasma cell proliferation. Science, 2025, 387, 413-420.	38.2	0
2	Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2025, 17, .	13.1	0
3	Role of affinity in plasma cell development in the germinal center light zone. Journal of Experimental Medicine, 2024, 221, .	8.1	3
4	SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity. MBio, 2024, 15, .	4.5	5
5	Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques. Science, 2024, 383, 1104-1111.	38.2	5
6	Transcription of HIV-1 at sites of intact latent provirus integration. Journal of Experimental Medicine, 2024, 221, .	8.1	1
7	Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. Nature Communications, 2023, 14, .	14.1	25
8	CD4 binding site immunogens elicit heterologous antiâ€“HIV-1 neutralizing antibodies in transgenic and wild-type animals. Science Immunology, 2023, 8, .	14.0	4
9	Memory B cell development elicited by mRNA booster vaccinations in the elderly. Journal of Experimental Medicine, 2023, 220, .	8.1	5
10	Impact of misclassified defective proviruses on HIV reservoir measurements. Nature Communications, 2023, 14, .	14.1	10
11	Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nature Medicine, 2023, 29, 2547-2558.	25.6	23
12	Continually recruited naÃ¯ve T cells contribute to the follicular helper and regulatory T cell pools in germinal centers. Nature Communications, 2023, 14, .	14.1	8
13	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.7	51
14	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe, The, 2022, 3, e203-e214.	12.5	44
15	Germinal Centers. Annual Review of Immunology, 2022, 40, 413-442.	30.9	350
16	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. New England Journal of Medicine, 2022, 386, 599-601.	25.5	322
17	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. Nature Communications, 2022, 13, .	14.1	15
18	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity, 2022, 55, 998-1012.e8.	22.7	81

#	Article	IF	Citations
19	Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022, 606, 368-374.	40.1	101
20	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	40.1	185
21	Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature, 2022, 606, 585-593.	40.1	315
22	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infectious Diseases, 2022, 9, .	0.8	5
23	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.7	132
24	Combination anti-HIV antibodies provide sustained virological suppression. Nature, 2022, 606, 375-381.	40.1	93
25	CRISPR comes a-knock-in to reprogram antibodies in vivo. Nature Biotechnology, 2022, , .	18.1	1
26	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	8.1	12
27	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, .	8.1	4
28	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	8.1	11
29	A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. Science Advances, 2022, 8, .	11.3	10
30	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. Journal of Experimental Medicine, 2022, 219, .	8.1	35
31	Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nature Medicine, 2022, 28, 2424-2435.	25.6	55
32	HIV-1 CD4-binding site germline antibodyâ€“Env structures inform vaccine design. Nature Communications, 2022, 13, .	14.1	7
33	Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nature Communications, 2022, 13, .	14.1	35
34	Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature, 2022, 613, 735-742.	40.1	68
35	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	13.1	342
36	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates. Journal of Virology, 2021, 95, .	3.6	18

#	Article	IF	Citations
37	Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. Journal of Experimental Medicine, 2021, 218, .	8.1	37
38	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	40.1	1,210
39	Persistent cellular immunity to SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	8.1	93
40	Dynamic regulation of TFH selection during the germinal centre reaction. Nature, 2021, 591, 458-463.	40.1	65
41	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	40.1	996
42	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. Journal of Virology, 2021, 95, .	3.6	46
43	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. EBioMedicine, 2021, 65, 103252.	10.0	14
44	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	40.1	98
45	Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. Journal of Experimental Medicine, 2021, 218, .	8.1	34
46	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clinical Chemistry, 2021, 67, 1249-1258.	1.1	11
47	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. Aids, 2021, 35, 1567-1574.	2.6	5
48	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	40.1	521
49	Germinal centerâ€“dependent and â€“independent memory B cells produced throughout the immune response. Journal of Experimental Medicine, 2021, 218, .	8.1	64
50	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282.	40.1	160
51	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 2021, 384, 2212-2218.	25.5	543
52	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathogens, 2021, 17, e1009688.	4.5	13
53	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, .	14.1	255
54	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Reports, 2021, 36, 109450.	6.4	38

#	Article	IF	Citations
55	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 2021, 12, .	14.1	71
56	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	22.7	202
57	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	14.0	407
58	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	6.4	62
59	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 2021, 600, 512-516.	40.1	139
60	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Science Translational Medicine, 2021, 13, .	13.1	53
61	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	8.1	220
62	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	40.1	204
63	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. Npj Vaccines, 2021, 6, .	5.8	2
64	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. Journal of Experimental Medicine, 2021, 218, .	8.1	36
65	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, .	13.1	31
66	A humanized mouse model of chronic COVID-19. Nature Biotechnology, 2021, 40, 906-920.	18.1	73
67	Isolation of single HIV-1 Envelope specific B cells and antibody cloning from immunized rhesus macaques. Journal of Immunological Methods, 2020, 478, 112734.	1.5	11
68	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. Cell Reports Medicine, 2020, 1, 100123.	7.3	56
69	Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18719-18728.	7.7	16
70	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687.	40.1	1,059
71	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	40.1	1,358
72	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. Antibodies, 2020, 9, 36.	2.6	12

#	Article	IF	Citations
73	We are here for you and ready to hear from you. Journal of Experimental Medicine, 2020, 217, .	8.1	0
74	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	8.1	409
75	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. Journal of Experimental Medicine, 2020, 217, .	8.1	74
76	Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates. Cell, 2020, 183, 1298-1311.e11.	35.1	141
77	JEM goes viral. Journal of Experimental Medicine, 2020, 217, .	8.1	0
78	An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24957-24963.	7.7	16
79	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	38.2	1,612
80	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	38.2	1,884
81	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	25.6	91
82	Single-Cell Sorting of HBsAg-Binding Memory B Cells from Human Peripheral Blood Mononuclear Cells and Antibody Cloning. STAR Protocols, 2020, 1, 100129.	1.1	7
83	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	35.1	542
84	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host and Microbe, 2020, 28, 335-349.e6.	15.2	51
85	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. Nature Communications, 2020, 11, .	14.1	13
86	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7981-7989.	7.7	22
87	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Journal of Virology, 2020, 94, .	3.6	24
88	Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9865-9875.	7.7	8
89	All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature, 2020, 586, 501-502.	40.1	19
90	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nature Medicine, 2020, 26, 222-227.	25.6	111

#	Article	IF	Citations
91	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. , 2020, , .		28
92	Risk of Zika microcephaly correlates with features of maternal antibodies. Journal of Experimental Medicine, 2019, 216, 2302-2315.	8.1	40
93	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 2019, 14, e0219142.	2.5	61
94	Protein Amounts of the MYC Transcription Factor Determine Germinal Center B Cell Division Capacity. Immunity, 2019, 51, 324-336.e5.	22.7	111
95	Anti-idiotypic antibodies elicit anti-HIV-1â€“specific B cell responses. Journal of Experimental Medicine, 2019, 216, 2316-2330.	8.1	22
96	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. Journal of Experimental Medicine, 2019, 216, 2253-2264.	8.1	81
97	JEM Editorial Board: Expanding on the basis of cancer. Journal of Experimental Medicine, 2019, 216, 1725-1725.	8.1	0
98	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. Journal of Virology, 2019, 93, .	3.6	54
99	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	22.7	66
100	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	40.1	122
101	HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. Journal of Experimental Medicine, 2019, 216, 1301-1310.	8.1	72
102	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nature Medicine, 2019, 25, 547-553.	25.6	178
103	Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nature Medicine, 2018, 24, 604-609.	25.6	103
104	A single injection of crystallizable fragment domainâ€“modified antibodies elicits durable protection from SHIV infection. Nature Medicine, 2018, 24, 610-616.	25.6	87
105	Antiâ€“HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4743-4748.	7.7	73
106	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nature Communications, 2018, 9, .	14.1	72
107	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. Journal of Virology, 2018, 92, .	3.6	34
108	Relationship between intact HIV-1 proviruses in circulating CD4 ⁺ T cells and rebound viruses emerging during treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.7	58

#	Article	IF	Citations
109	The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination. Molecular Cell, 2018, 72, 636-649.e8.	14.2	31
110	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	40.1	372
111	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine, 2018, 24, 1701-1707.	25.6	188
112	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host and Microbe, 2018, 24, 579-592.e4.	15.2	74
113	Relationship between latent and rebound viruses in a clinical trial of antiâ€“HIV-1 antibody 3BNC117. Journal of Experimental Medicine, 2018, 215, 2311-2324.	8.1	87
114	Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. Nature Immunology, 2018, 19, 973-985.	13.1	94
115	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	4.5	65
116	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, .	13.1	120
117	A time of change. Journal of Experimental Medicine, 2017, 214, 1-2.	8.1	2
118	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine, 2017, 23, 185-191.	25.6	374
119	RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks. Journal of Experimental Medicine, 2017, 214, 815-831.	8.1	17
120	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell, 2017, 169, 597-609.e11.	35.1	247
121	HIV: Persistence through division. Journal of Experimental Medicine, 2017, 214, 875-876.	8.1	1
122	Early antibody therapy can induce long-lasting immunity to SHIV. Nature, 2017, 543, 559-563.	40.1	245
123	Progress toward active or passive HIV-1 vaccination. Journal of Experimental Medicine, 2017, 214, 3-16.	8.1	104
124	The cell cycle restricts activation-induced cytidine deaminase activity to early G1. Journal of Experimental Medicine, 2017, 214, 49-58.	8.1	54
125	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine, 2017, 214, 2573-2590.	8.1	128
126	The microanatomic segregation of selection by apoptosis in the germinal center. Science, 2017, 358, .	38.2	193

#	Article	IF	Citations
127	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection InÂVivo. Cell, 2017, 170, 637-648.e10.	35.1	111
128	JEM Advisory Editorial Board: Increasing diversity. Journal of Experimental Medicine, 2017, 214, 2169-2169.	8.1	1
129	The new face of JEM. Journal of Experimental Medicine, 2017, 214, 3467-3467.	8.1	0
130	Author response: Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. , 2017, , .		0
131	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.5	152
132	Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nature Communications, 2016, 7, .	14.1	135
133	Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory. Immunity, 2016, 44, 769-781.	22.7	107
134	Inducible targeting of cDCs and their subsets in vivo. Journal of Immunological Methods, 2016, 434, 32-38.	1.5	57
135	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature, 2016, 533, 105-109.	40.1	263
136	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell, 2016, 166, 1445-1458.e12.	35.1	235
137	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity, 2016, 45, 483-496.	22.7	293
138	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, .	7.7	143
139	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nature Structural and Molecular Biology, 2016, 23, 906-915.	6.4	153
140	Human studies at JEM: Immunology and beyond. Journal of Experimental Medicine, 2016, 213, 467-468.	8.1	3
141	Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. Journal of Experimental Medicine, 2016, 213, 2861-2870.	8.1	113
142	Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. New England Journal of Medicine, 2016, 375, 2019-2021.	25.5	62
143	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell, 2016, 165, 1609-1620.	35.1	119
144	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature, 2016, 535, 556-560.	40.1	381

#	Article	IF	Citations
145	Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. Journal of Experimental Medicine, 2016, 213, 517-534.	8.1	98
146	Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. Journal of Clinical Investigation, 2016, 126, 415-423.	9.1	59
147	Author response: Structural basis for germline antibody recognition of HIV-1 immunogens. , 2016, , .		0
148	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	4.5	44
149	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	35.1	257
150	Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. Journal of Experimental Medicine, 2015, 212, 385-399.	8.1	208
151	Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient. Journal of Immunological Methods, 2015, 418, 61-65.	1.5	8
152	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015, 519, 87-91.	40.1	249
153	Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell, 2015, 160, 433-446.	35.1	99
154	HIV-1 Integration Landscape during Latent and Active Infection. Cell, 2015, 160, 420-432.	35.1	348
155	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. Journal of Virology, 2015, 89, 2659-2671.	3.6	116
156	Circulating precursors of human CD1c+ and CD141+ dendritic cells. Journal of Experimental Medicine, 2015, 212, 401-413.	8.1	171
157	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell, 2015, 161, 1505-1515.	35.1	210
158	Collecting Lymphatic Vessel Permeability Facilitates Adipose Tissue Inflammation and Distribution of Antigen to Lymph Nodeâ€“Homing Adipose Tissue Dendritic Cells. Journal of Immunology, 2015, 194, 5200-5210.	0.6	99
159	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015, 522, 487-491.	40.1	621
160	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature Communications, 2015, 6, .	14.1	76
161	Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. Cell, 2015, 162, 727-737.	35.1	130
162	Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching. Nature, 2015, 525, 134-139.	40.1	87

#	Article	IF	Citations
163	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. MBio, 2015, 6, .	4.5	20
164	Clonal analysis of human dendritic cell progenitor using a stromal cell culture. Journal of Immunological Methods, 2015, 425, 21-26.	1.5	32
165	An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex. Journal of Allergy and Clinical Immunology, 2015, 135, 998-1007.e6.	2.8	38
166	Epigenetic targeting of activation-induced cytidine deaminase. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18667-18672.	7.7	46
167	Convergent Transcription at Intragenic Super-Enhancers Targets AID-Initiated Genomic Instability. Cell, 2014, 159, 1538-1548.	35.1	205
168	B Cell Super-Enhancers and Regulatory Clusters Recruit AID Tumorigenic Activity. Cell, 2014, 159, 1524-1537.	35.1	217
169	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372.	8.1	71
170	L-Myc expression by dendritic cells is required for optimal T-cell priming. Nature, 2014, 507, 243-247.	40.1	64
171	Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature, 2014, 509, 637-640.	40.1	443
172	A robust pipeline for rapid production of versatile nanobody repertoires. Nature Methods, 2014, 11, 1253-1260.	14.5	338
173	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 2014, 211, 2061-2074.	8.1	268
174	Identification of chromosomal translocation hotspots via scan statistics. Bioinformatics, 2014, 30, 2551-2558.	5.0	23
175	Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. Journal of Experimental Medicine, 2014, 211, 1875-1891.	8.1	87
176	Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. Cell, 2014, 158, 989-999.	35.1	317
177	Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for InÂVivo Activity. Cell, 2014, 158, 1243-1253.	35.1	392
178	Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy. Cell, 2014, 156, 633-648.	35.1	282
179	Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. Cell Reports, 2014, 7, 785-795.	6.4	182
180	Antigen Delivery to CD11c+CD8â^' Dendritic Cells Induces Protective Immune Responses against Experimental Melanoma in Mice In Vivo. Journal of Immunology, 2014, 192, 5830-5838.	0.6	59

#	Article	IF	Citations
181	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity, 2013, 39, 245-258.	22.7	291
182	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Î”cBaL. Journal of Immunological Methods, 2013, 397, 47-54.	1.5	8
183	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	7.7	228
184	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature, 2013, 503, 224-228.	40.1	546
185	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature, 2013, 503, 277-280.	40.1	396
186	Antibodies in HIV-1 Vaccine Development and Therapy. Science, 2013, 341, 1199-1204.	38.2	393
187	Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6049-6054.	7.7	55
188	Chromosome Translocation, B Cell Lymphoma, and Activation-Induced Cytidine Deaminase. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 79-103.	31.8	146
189	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. Cell, 2013, 153, 126-138.	35.1	427
190	Roadmaps to a vaccine. Nature, 2013, 496, 441-442.	40.1	26
191	Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model. Journal of Virology, 2013, 87, 8535-8544.	3.6	21
192	Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. Journal of Experimental Medicine, 2013, 210, 2813-2821.	8.1	137
193	Computational analysis of antiâ€“HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10598-10603.	7.7	91
194	Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains. Journal of Virology, 2013, 87, 10047-10058.	3.6	62
195	Restricting HIV-1 pathways for escape using rationally designed antiâ€“HIV-1 antibodies. Journal of Experimental Medicine, 2013, 210, 1235-1249.	8.1	83
196	Enhanced HIV-1 neutralization by antibody heteroligation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 875-880.	7.7	46
197	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, .	7.7	193
198	A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15859-15864.	7.7	68

#	Article	IF	Citations
199	Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, .	7.7	460
200	Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood, 2012, 120, 2240-2248.	1.0	302
201	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	40.1	426
202	A Blueprint for HIV Vaccine Discovery. Cell Host and Microbe, 2012, 12, 396-407.	15.2	327
203	The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nature Immunology, 2012, 13, 1083-1091.	13.1	370
204	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	8.1	135
205	Germinal Centers. Annual Review of Immunology, 2012, 30, 429-457.	30.9	1,553
206	Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. Journal of Experimental Medicine, 2012, 209, 1153-1165.	8.1	412
207	Translocation capture sequencing: A method for high throughput mapping of chromosomal rearrangements. Journal of Immunological Methods, 2012, 375, 176-181.	1.5	21
208	Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses. PLoS ONE, 2011, 6, e24078.	2.5	94
209	Translocation-Capture Sequencing Reveals the Extent and Nature of Chromosomal Rearrangements in B Lymphocytes. Cell, 2011, 147, 95-106.	35.1	302
210	Differential regulation of self-reactivity discriminates between IgG⁺human circulating memory B cells and bone marrow plasma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18044-18048.	7.7	74
211	A dynamic T cellâ€“limited checkpoint regulates affinity-dependent B cell entry into the germinal center. Journal of Experimental Medicine, 2011, 208, 1243-1252.	8.1	325
212	Ralph Steinman (1943â€“2011). Nature, 2011, 478, 460-460.	40.1	6
213	Polyreactive antibodies in adaptive immune responses to viruses. Cellular and Molecular Life Sciences, 2011, 69, 1435-1445.	5.6	100
214	Development and Migration of Plasma Cells in the Mouse Lymph Node. Immunity, 2010, 33, 118-127.	22.7	113
215	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.	40.1	361
216	Anti-gp41 Antibodies Cloned from HIV-Infected Patients with Broadly Neutralizing Serologic Activity. Journal of Virology, 2010, 84, 5032-5042.	3.6	47

#	Article	IF	Citations
217	Human antiâ€“HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. Journal of Experimental Medicine, 2010, 207, 1995-2002.	8.1	56
218	Origin of Chromosomal Translocations in Lymphoid Cancer. Cell, 2010, 141, 27-38.	35.1	252
219	Germinal Center Dynamics Revealed by Multiphoton Microscopy withÂa Photoactivatable Fluorescent Reporter. Cell, 2010, 143, 592-605.	35.1	926
220	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science, 2010, 329, 811-817.	38.2	961
221	Germinal center reutilization by newly activated B cells. Journal of Experimental Medicine, 2009, 206, 2907-2914.	8.1	88
222	A method for identification of HIV gp140 binding memory B cells in human blood. Journal of Immunological Methods, 2009, 343, 65-67.	1.5	175
223	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009, 458, 636-640.	40.1	741
224	AID Produces DNA Double-Strand Breaks in Non-Ig Genes and Mature B Cell Lymphomas with Reciprocal Chromosome Translocations. Molecular Cell, 2009, 36, 631-641.	14.2	205
225	Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. Journal of Immunological Methods, 2008, 329, 112-124.	1.5	820
226	AID Is Required for the Chromosomal Breaks in c-myc that Lead to c-myc/IgH Translocations. Cell, 2008, 135, 1028-1038.	35.1	372
227	Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9727-9732.	7.7	197
228	Autoreactivity in Human IgG+ Memory B Cells. Immunity, 2007, 26, 205-213.	22.7	411
229	T-independent type II immune responses generate memory B cells. Journal of Experimental Medicine, 2006, 203, 305-310.	8.1	230
230	Somatic Hypermutation Is Limited by CRM1-dependent Nuclear Export of Activation-induced Deaminase. Journal of Experimental Medicine, 2004, 199, 1235-1244.	8.1	195
231	Predominant Autoantibody Production by Early Human B Cell Precursors. Science, 2003, 301, 1374-1377.	38.2	1,654
232	OcaB regulates transitional B cell selection. International Immunology, 2003, 15, 1099-1104.	3.4	20
233	Role of antigen receptor affinity in T cellâ€“independent antibody responses in vivo. Nature Immunology, 2002, 3, 399-406.	13.1	221
234	Role of BCR affinity in T cellâ€“dependent antibody responses in vivo. Nature Immunology, 2002, 3, 570-575.	13.1	253

#	Article	IF	Citations
235	AID is required to initiate Nbs1/Î³-H2AX focus formation and mutations at sites of class switching. Nature, 2001, 414, 660-665.	40.1	433
236	Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo. Journal of Experimental Medicine, 2001, 194, 769-780.	8.1	1,536
237	Circulating human B cells that express surrogate light chains and edited receptors. Nature Immunology, 2000, 1, 207-213.	13.1	105
238	Antibody regulation of B cell development. Nature Immunology, 2000, 1, 379-385.	13.1	209
239	DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature, 2000, 404, 510-514.	40.1	468
240	A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Human Immunology, 2000, 61, 729-738.	1.0	108
241	Secondary V(D)J recombination in B-1 cells. Nature, 1999, 397, 355-359.	40.1	61
242	V(D)J Recombination: Modulation of RAG1 and RAG2 Cleavage Activity on 12/23 Substrates by Whole Cell Extract and DNA-bending Proteins. Journal of Experimental Medicine, 1997, 185, 2025-2032.	8.1	122
243	Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. Nature, 1996, 382, 551-555.	40.1	574
244	The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. Nature, 1996, 383, 542-547.	40.1	226
245	The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature, 1995, 375, 151-155.	40.1	801
246	Structural basis for germline antibody recognition of HIV-1 immunogens. ELife, 0, 5, .	1.6	61
247	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. ELife, 0, 6, .	1.6	39
248	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 0, 9, .	1.6	961
249	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 0, 9, .	1.6	10